SCHEMBL20207772

SCHEMBL20207772

NC(=O)c1c(COCc2ccccc2)nn(Cc2ccc(C(F)(F)F)cc2)c1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.52
MAPK1 P28482 1/20 0.43
GHSR Q92847 1/20 0.41
PTGDR2 Q9Y5Y4 4/20 0.41
MAOB P27338 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGER4 P35408 2/20 0.39
FSCN1 Q16658 1/20 0.39
MDM2 Q00987 1/20 0.39
HDAC1 Q13547 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38
SLC6A5 Q9Y345 1/20 0.38
AURKA O14965 1/20 0.37
RPS6KB1 P23443 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20202573 0.86 MAPK1 (0.51) PDE2AMAPK1PTGDR2MAOBKDM4E
SCHEMBL20138445 0.84 PDE2A (0.54) PDE2AGHSRPTGDR2MAOBMDM2
SCHEMBL18290836 0.84 PTGDR2 (0.42) PDE2AMAPK1PTGDR2MAOBSLC6A5
SCHEMBL18282926 0.80 PDE2A (0.76) PDE2AGHSRPTGDR2MDM2
SCHEMBL20185362 0.80 TSHR (0.51) PDE2AGHSRPTGDR2MAOBPTGER4
SCHEMBL6197831 0.80 PDE2A (0.52) PDE2AMAPK1GHSRMAOBKDM4E
SCHEMBL20138417 0.79 PDE2A (0.66) PDE2AGHSRMDM2
SCHEMBL6196995 0.78 PDE2A (0.50) PDE2AMAPK1GHSRKDM4EALDH1A1
SCHEMBL18282725 0.77 PDE2A (0.59) PDE2AGHSRMAOBMDM2
SCHEMBL18290839 0.76 MAPK1 (0.51) MAPK1PTGDR2KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302486-B1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-09-30 EP disclosed
US-10174037-B2 Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2019-01-08 US disclosed
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D PDE2A 2/4885MAPK1 1139/4885GHSR 1735/4885
US-10174037-B2 Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors PDE12, PDE2A, PDE4D PDE2A 2/4885MAPK1 1139/4885GHSR 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.